China Boton Group Company Limited reported a 25.3% year-on-year rise in interim revenue to RMB 798.84 million for the six months ended 30 June 2026, driven by a 58.1% surge in e-cigarette sales to RMB 422.45 million. Gross profit improved 17.2% to RMB 233.14 million, yet higher operating costs and financing charges compressed profitability: group net profit slid 74.5% to RMB 2.22 million, while profit attributable to shareholders swung to a loss of RMB 29.96 million (1H25: RMB 8.12 million loss). Basic loss per share widened to RMB 0.03.
Segment performance was mixed. Tobacco flavors revenue fell 7.9% to RMB 165.24 million amid softer demand, while food flavors and fine fragrances gained 24.3% and 5.5% respectively. Rental income from investment properties declined 26.2% to RMB 18.36 million as certain leases ended in a weak Shenzhen property market.
Operating cash outflow reached RMB 42.16 million (1H25: inflow of RMB 6.07 million). A RMB 2.49 billion compensation for the compulsory resumption of Shenzhen land lifted investing cash flow to RMB 2.26 billion and funded a RMB 1.08 billion net repayment of borrowings. Total debt fell to RMB 1.16 billion from RMB 2.20 billion at end-2025, cutting the debt-to-equity ratio to 48.3% (2025-end: 92.1%). Cash and restricted deposits closed the period at RMB 1.57 billion.
The land compensation was booked as a current liability of RMB 2.49 billion at 30 June; the transaction completed in July 2026. Excluding items linked to the land deal, management calculates adjusted net current assets of about RMB 2.05 billion and an adjusted current ratio of 3.41.
Capital expenditure totalled RMB 53.40 million, well below last year’s RMB 241.62 million following completion of major projects. Committed capex stood at RMB 178.16 million, including a pending RMB 240.00 million acquisition of Shanghai Longyin Biotechnology, whose property assets will provide R&D space and rental income.
No interim dividend was declared. The board cited ongoing investments and market uncertainties as it focuses on strengthening compliance, enhancing R&D and diversifying revenue streams across domestic and overseas markets.